Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax improved outcomes for untreated chronic lymphocytic leukemia ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...
For patients diagnosed with locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), the first line of therapy often represents the most meaningful opportunity to ...
In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results